OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 17, 2024
Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.
May 16, 2024
Webinar Date/Time: Wednesday, May 29th 11am EDT | 4pm GMT | 5pm CEST
Webinar Date/Time: Wed, Jun 12, 2024 11:00 AM EDT
May 11, 2024
Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.
May 10, 2024
At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.
May 09, 2024
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.
May 08, 2024
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
May 07, 2024
Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.